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Amphiregulin (AR) involvement in liver fibrogenesis and hepatic stellate cells (HSC) regulation is under
study. Non-alcoholic fatty liver disease (NAFLD) and its more severe form non-alcoholic steatohepatitis
(NASH) may progress to cirrhosis and hepatocellular cancer (HCC). Our aim was to investigate ex vivo the
effect of AR on human primary HSC (hHSC) and verify in vivo the relevance of AR in NAFLD fibrogenesis.
hHSC isolated from healthy liver segments were analyzed for expression of AR and its activator, TNF-a
converting enzyme (TACE). AR induction of hHSC proliferation and matrix production was estimated in
the presence of antagonists. AR involvement in fibrogenesis was also assessed in a mouse model of NASH
and in humans with NASH. hHSC time dependently expressed AR and TACE. AR increased hHSC
proliferation through several mitogenic signaling pathways such as EGFR, PI3K and p38. AR also induced
marked upregulation of hHSC fibrogenicmarkers and reduced hHSCdeath. AR expressionwas enhanced in
the HSC of a murine model of NASH and of severe human NASH. In conclusion, AR induces hHSC
fibrogenic activity via multiple mitogenic signaling pathways, and is upregulated in murine and human
NASH, suggesting that AR antagonists may be clinically useful anti-fibrotics in NAFLD.
N
on-alcoholic fatty liver disease (NAFLD), the commonest cause of chronic liver disease in affluent
countries, is a spectrum of liver diseases ranging from hepatic steatosis (simple intrahepatic accumula-
tion of lipid droplets) through steatosis with inflammation and fibrosis (non-alcoholic steatohepatitis,
NASH) to cirrhosis and hepatocellular cancer (HCC)1,2. Hepatic stellate cells (HSC), found in the space of Disse
(perisinusoidal space between sinusoids and hepatocytes), are the predominant fibrogenic cells in the liver, are
activated by liver injury to trans-differentiate from a quiescent state to proliferative matrix producing myofibro-
blasts3. Excessivematrix productionmay result in cirrhosis with the possibility of HCC onset, althoughHCCmay
also develop in a minority of cases in a background of NAFLD/NASH without cirrhosis4,5.
The epidermal growth factor receptor (EGFR) ligand amphiregulin (AR) plays a central role in branching
morphogenesis in organs and is expressed both in healthy and in cancer tissues. It is an autocrine growth factor as
well as amitogen for fibroblasts and regulatory T-cells6. Various studies have highlighted the functional role of AR
in multiple aspects of tumorigenesis, including transducing growth signals, modulating tissue invasion and
metastasis, angiogenesis, and resistance to apoptosis7. AR participates in the modulation of the hepatic acute-
phase reaction that occurs during inflammation and liver regeneration, and is important for allowing normal
hepatocellular proliferation and the restoration of homeostasis8. AR has also been shown to be a trigger of liver
regeneration after partial hepatectomy9,10.
The association of AR expression with liver disease has been demonstrated in different animal models of liver
damage and in human samples. AR is induced in the fibrotic liver of mice chronically treated with CCl4 and in
models of acute liver damage induced by CCl4, activation of Fas and LPS administration, AR induction was also
demonstrated in the liver of cirrhotic patients and rats, as well as in human HCC, suggesting that AR is also
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implicated in hepatic carcinogenesis9,11–14. Moreover, it has been
suggested to protect from immune mediated liver injury10. Interes-
tingly, AR has been suggested to be pro-fibrogenic since mice lacking
AR develop less hepatic fibrosis after carbon tetrachloride challenge
compared to wild type littermates15. However, our understanding of
AR function in NASH is far from being complete and, importantly,
whether and how AR regulates human (h) HSCs, the major cellular
determinant of hepatic fibrosis in NASH, and plays a role in demo-
graphically important specific human liver diseases such as NAFLD/
NASH is under study.
In this study, our aims were primarily to study the ex vivo role of AR
signaling mechanisms in the fibrogenic physiology of primary hHSC,
and secondarily to determine the in vivo significance and disease rel-
evance of these findings by assaying AR in the HSC compartment of a
mouse model of NASH and of human livers with NAFLD/NASH at
different stages of severity. We show for the first time that AR is
expressed in hHSC; further and importantly, we describe AR up-regu-
lation in the HSC of mice and patients with NASH.
Results
AR expression in hHSC increases in early passages and parallels
ASMA expression and TACE activation. AR has been detected in
the whole liver but has not previously been reported specifically in
HSC. To determine if AR is expressed by freshly isolated (quiescent)
HSC and activated HSC we analysed hHSC for AR mRNA and
protein expression, as shown in Figure 1: on days 0 and 2 when
quiescent, and day 4 and 10 when activated. hHSC expressed AR
mRNA and protein, with expression levels at day 4 greater than that
at day 10, at which time AR expression became lower at the mRNA
level and returned to basal as for protein levels (Figure 1A and 1C).
We then analysed the mRNA and protein expression of the AR
regulating factor tumour necrosis factor (TNF) a converting
enzyme (TACE), which is known to solubilise AR and promote its
interaction with its cognate receptors, including EGFR16. We found
that TACE was expressed by hHSC and its mRNA, protein and
activity levels reach all peak values preceding the one of AR
mRNA and protein (Figure 1B, 1C and 1D), suggesting that in
hHSC TACE is likely to be required for activation of AR. These
observations were corroborated by immunocytochemistry data
showing that AR expression was confirmed at peak levels at day 2–
4, with expression at day 10 lower than that at day 4 (Figure 2).
Parallel analysis of the expression of a-smooth muscle actin
(ASMA), a marker of HSC activation17, showed a progressive
increase from day 0, clearly indicating that AR expression
Figure 1 | AR mRNA expression in hHSC. (A) Cultures of hHSC show significantly higher expression (* p, 0.05) of AR by day 4 compared to day 0.
Expression is effectively reduced by day 10 (** p , 0.01). (B) AR mRNA expression is preceded by the up-regulation of the TACE gene, required
for AR activity. TACE expression is highest at day 2 (*p, 0.05) and is reduced by day 4 (**p, 0.01). (C)Western blot analysis for AR and TACE protein
levels in hHSC at day 0, 2, 4 and 10 (left panel); images were obtained from separate gels, run under the same experimental conditions, blotted on separate
PVDF membranes and processed for detection with the respective antibodies. Densitometric quantification normalized to b-actin levels (right panel).
Images are representative of three independent experiments (* p, 0.05; ** p, 0.01). (D) TACE activities in hHSC at day 0, 2, 4 and 10 were measured
using SensoLyte 520 TACE Activity Assay kit. N 5 3, ** p , 0.01.
www.nature.com/scientificreports
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preceded that of ASMA which increased progressively from day 0,
indicating that AR expression preceded that of ASMA (Figure 2).
Our findings also clearly show that hHSC were AR producing cells
because of the observed co-localisation of ASMA and AR (Figure 2).
Exogenous AR stimulates proliferation of hHSC. AR has been
suggested to be pro-fibrogenic because mice lacking AR develop
less hepatic fibrosis after carbon tetrachloride challenge compared
to controls15, but whether this effect of AR is directly dependent on
HSC is not known. Here, we found that AR significantly enhanced
hHSC proliferation with a maximal effect at 100 pg/ml (Figure 3A).
To further explore these proliferation effects, equal numbers of
hHSC were seeded into 96-well plates and grown under serum free
(SF) conditions, 10% fetal bovine serum (FBS) or with AR (10 pg/
mL) plus 10% FBS. As expected, an increased number of cell nuclei
was visible between FBS and FBS plus AR (10 pg/mL) conditions
compared to SF (Figure 3B). In addition, annexin-PI staining by flow
cytometry demonstrated a significantly higher number of live cells in
the AR 1 FBS condition compared to FBS alone (Figure 3C).
AR-induced hHSC proliferation requires EGFR and the PI3K,
MEK, p38 MAPK, PKC survival pathways. AR is thought to act
through the EGFR in non-liver cells18, but whether its action in
hHSC is similarly mediated via EGFR is not known. We show
here that treatment with EGFR antagonist PD153035 markedly
inhibits AR-induced hHSC proliferation (Figure 4A), pointing for
the first time to a role for EGFR in AR-induced hHSC proliferation.
Previous studies have shown that AR influenced the phosphorylation
of one or more growth signals and MAP kinases involved in the
proliferation of vascular smooth muscle cells19. Consistently, here
we find that culturing hHSC with AR (10 pg/mL) triggers
activation of EGFR, AKT, ERK1/2 and p38 MAP kinases, as
evidenced by increased phosphorylation levels on key residues
[pEGFR(Y1068), pAKT(Ser473), pERK1/2(Thr202/Tyr204) and p-
p38(Thr180/Tyr182)] (Figure 4B).To confirm that several mitogenic
pathways, other than EGF signalling, are involved in AR-induced
hHSC proliferation, we cultured hHSC with AR in the presence of
various specific inhibitors20: pertussis toxin (G-protein inhibitor,
100 nM), wortmannin (PI3K inhibitor, 100 nM), PD98059 (MEK
inhibitor, 100 nM), SB202190 (p38 MAPK inhibitor, 10 mM), and
Ro-32-0432 (PKC inhibitor, 1 mM). Our data show that blockage of
intra-cellular mitogenic kinases invariably dampen AR-induced
hHSC proliferation (Figure 4C). The most potent reductions were
observed after treatment with wortmannin and SB202190, indicating
that the PI3K and p38 MAPK pathways are of particular importance
in AR-induced hHSC proliferation (Figure 4C).
AR induces fibrogenic markers in hHSC and is upregulated in a
murine model of NASH. Besides proliferation, a characteristic of
activated hHSC is the production ofmatrix proteins such as collagen,
and over-exuberant matrix over-production results in fibrosis and
cirrhosis21. The effect of AR on the induction of collagen in hHSC is
not known. We analysed the induction of hHSC collagen 1a2 gene
expression in the presence of AR. As shown in Figure 5A, AR
increased dose-dependently hHSC collagen 1a2 gene expression of
2 to 3 fold in primary hHSC. Similar findings were obtained for
ASMA mRNA expression (data not shown). The effect is
comparable to the effect of the pro-fibrogenic cytokine TGF-b
used here as a positive control22 (Figure 5A).
To confirm the in vivo relevance of these cellular studies, C57/B6
mice were fed for 4 weeks either normal chow or a methionine cho-
line-deficient (MCD) diet, a well-known regimen inducing NASH23,24.
Mice fed a MCD diet had a more abundant hepatic mRNA expression
of AR of about 5 times compared to controls (Figure 5B). To discern if
the increase in hepatic AR was due to an increase of its expression in
hepatocytes (the predominant hepatic cell type) or in HSC, we isolated
hepatocytes and HSC (mouse HSC, mHSC) from the livers of control
c57/B6 mice and mice fed a MCD diet, and measured AR protein
expression by immunoblotting (Figure 5C): while AR protein express-
ion was detected in hepatocytes at similar levels in control and MCD
fed mice, it was significantly higher in mHSC and enhanced in mHSC
isolated from the NASH model (Figure 5C), confirming mRNA data
and highlighting a predominant role of mHSC in NASH-dependent
increase in AR expression.
AR is increased in human patients scored for NASH. To study in
humans the in vivo relevance of these ex vivo and animal studies, we
analyzed specimens obtained from healthy liver segments of patients
undergoing resection of metastases and compared them to samples
from patients with histologically proven NASH scored for fibrosis
according to both Brunt andNAFLDActivity Score (NAS) of fibrosis
severity25,26. Semi-quantitative RT-PCR analysis of liver RNA from
Figure 2 | AR expression in hHSC detected by immunofluorescence. Myofibroblastic transformation in culture at day 2 and 4 resulted in a transient
increase in AR complemented by a-smooth muscle actin (ASMA) expression, a known indicator of fibrosis. AR was reduced by day 10 in
culture while ASMA remains.
www.nature.com/scientificreports
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controls and from patients with NASH induced cirrhosis
demonstrated a marked upregulation of AR in human livers with
NASH compared with controls, where it was only minimally
expressed (Figure 6A). Quantification of AR expression in these
samples confirmed that AR expression was approximately 6-fold
greater in NASH livers compared to controls (Figure 6B).
These results were corroborated by immunohistochemical ana-
lyses of liver biopsies from patients with increased fibrosis scores
(F1, F2, F3 and F4), as visualized by Masson trichrome stainings
(Figure 7A). Immunopositivity for AR and for fibrogenic marker
ASMA in hHSC was present and abundant only in F3 and F4, with
F4. F3, whereas virtually no positive hHSC were detected in F1 and
F2 (Figure 7B and 7C).
Discussion
HSCs have previously been identified as the primary subtype
responsible for remodeling liver tissue following injury27; . However,
the factors that stimulate their proliferation are not fully understood.
AR, a protein member of the EGFR-ligand family, is shown here to
act both as an hHSCmitogen in primary culture and also to influence
the production of hHSC matrix proteins (Figure 8). AR was also
shown to be up-regulated in a murine model of NASH and in
patients with liver scored for advanced levels of fibrosis and cirrhosis,
suggesting that ARmay be an important factor in a spectrum of liver
diseases ranging from NAFLD trough NASH to cirrhosis. This is
fully consistent with the association of AR expression and liver dis-
ease that has been previously shown in different animal models of
acute liver damage15,16 and in human samples with cirrhosis and
HCC14. AR has been widely described as a protein capable to induce
mitosis29 <. A link to human diseases was initially reported when AR
was found to be increased in patients with lung fibrosis29. The role of
AR in the liver is under investigation but has been reported to assist
in the recovery of hepatic tissues following injury10,12. This obser-
vation is interesting in respect to the liver, which defaults to hepatic
Figure 3 | Effect of exogenously added AR on hHSC proliferation. (A) Primary hHSC treated with AR in the picogram range (10 & 100 pgs) are induced
to proliferate. Cell division is significantly increased (* p , 0.05) compared to FBS (10%) control and to a known established stellate cell mitogen,
platelet derived growth factor (PDGF, 20 ng/ml). (B) Results were confirmed by DAPI staining which enumerated the number of new nuclei in FBS-
treated cells or AR (10 pg)1 FBS2 treated cells. (C) AR treatment (10 pg) of primary hHSC resulted in higher live cell populations as determined by flow
cytometry.
www.nature.com/scientificreports
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fibrogenesis as a means of regenerating injured tissue. Therefore, the
question is whether AR is expressed in the restorative HSCs and AR
level change upon HSCs activation is relevant.
AR is expressed as a 252 amino acid glycoprotein that exists stably
in an uncleaved pro-form (Plowman, 1990)35. AR activation has been
shown to require cleavage via the matrix-metalloproteinase TACE
(also known as ADAM17), allowing ‘‘shedding’’ of the ligand from
its plasma membrane anchoring and subsequent interaction with
cognate receptors17. Correspondingly, TACE mRNA levels were
observed to increase early in primary hHSC (day 2) and precede
the expression of AR (day 4), suggesting its activation from the
pro-form (Figure 1A, B). The rise in AR expression mirrors an
increase in ASMA during this period, indicating an association
between hHSC activation and AR expression. The activation of AR
might be expected to induce proliferation in HSC. AR is most com-
monly identified as a growth factor and acts as a mitogen in a varied
range of tissues, including keratinocytes, renal cells, and mammary
epithelial cells31–34. Consistently, HSC of AR knock-out mice show
an inability to proliferate at the same level as the ones of wild type
mice9,10. As expected, the exogenous addition of AR in the pico-
gram range was sufficient to stimulate proliferation of hHSC.
Furthermore, in addition to greater hHSC growth, live cell popula-
tions were increased while apoptosis levels did not change signifi-
cantly (data not shown). Thus, AR can act as a survival factor when
expressed in liver. The survival pathway by which AR operates has
only been partially described. AR has been previously shown to
interact with EGFR in various cell types and EGFR expression
may in fact constitute a requirement for liver recovery34. Data are
Figure 4 | Inhibition of AR-induced proliferative pathways in hHSC. (A) Proliferation was assessed via ELISA with and without EGFR receptor blocker
PD153035 (1 mmol/L). AR induced hHSC proliferation (*p , 0.001) that was prevented by blocking the EGF receptor (# p , 0.05). (B) Western blot
analysis for pEGFR(Y1068), EGFR, pAKT(Ser473), AKT, pERK1/2(Thr202/Tyr204), ERK1/2, p-p38(Thr180/Tyr182), p38 and b-actin was assayed in
primary hHSC cultured with AR (10 pg/ml). Images are representative of three independent experiments. Images were obtained from separate gels, run
under the same experimental conditions, blotted on separate PVDF membranes and processed for detection with the respective antibodies. Asterisks
indicate increased phosphorylation levels in presence of AR. (C) Involvement of mitogenic intracellular pathways in AR-induced hHSC proliferation was
assayed in primary hHSC cultured with AR and in the presence of specific inhibitors: pertussis toxin (G-protein inhibitor, 100 nM), wortmannin (PI3K
inhibitor, 100 nM), PD98059 (MEK inhibitor, 100 nM), SB202190 (p38MAPK inhibitor, 10 mM), and Ro-32-0432 (PKC inhibitor, 1 mM) (*p, 0.001).
www.nature.com/scientificreports
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emerging that AR is expressed at the onset of hepatocyte injury
within the liver either by partial hepatectomy or exposure to carbon
tetrachloride10. The protein is assumed to act through AKT and
potentially through one or more mitogen-activated protein (MAP)
kinase signaling pathways19. However, previous research has limited
investigations to only a few potential pathways. In this study, numer-
ous inhibitors have been employed to investigate a broad spectrum
of survival pathways including G-coupled proteins, MAP kinases,
and mitogens. Each inhibitor was shown to decrease the ability of
AR to induce a proliferative response compared to the addition of
AR alone. The results agree with previous reports that AR-EGFR
complexes are mediated through MAP kinase pathways, and our
investigations reveal that specifically the p38 and PI3 kinase path-
ways were the most affected by inhibitor treatment.
Ourwork and others have suggested that AR is capable of inducing
proliferation in multiple cell types. Additionally, our investigations
revealed that collagen 1a, ASMA and positive control TGF-bmRNA
are increased upon stimulation of AR in hHSCs (Figure 4 and data
not shown). Collagen 1a is important for recovery of damaged liver
tissues, but its over-production is a clinical hallmark of fibrosis36,37.
One question our investigation sought to answer was whether AR
was expressed in a model of liver injury. To understand if AR
expression is also associated with liver disease, its expression was
investigated initially in mice fed a MCD diet, known to induce fat
accumulation in the liver. The model, within its limitations, is able to
provoke NASH. Mice fed a MCD diet in fact showed AR up-regu-
lation associated with the presence of NASH specifically in HSC
rather than in hepatocytes. These data were corroborated by the
evaluation of biopsy specimens obtained from resected human livers
scored for increased levels of fibrosis and associated cirrhosis accord-
ing to both Brunt andNAFLDActivity Score (NAS) of fibrosis sever-
ity (scored from 1 to 4; 1 5 centrilobular/perisinusoidal; 2 5
Figure 5 | Effect of AR on collagen 1a2 production. (A) AR is capable of inducing collagen production at both picogram and nanogram concentrations
(*p , 0.05). The effect is similar to that of TGF-b, inductor of collagen production, a major step in the pathogenesis of fibrosis. (B) Mice were fed
either a normal chow diet or amethionine-choline deficient (MCD) diet modelling NASH.Mice onMCD diet expressed higher hepatic ARmRNA levels
than mice fed a normal chow diet (*p, 0.001). (C)Western blot analysis for AR protein levels in hepatocytes and mHSC isolated fromMCDmice (left
panel). Images were obtained from separate gels, run under the same experimental conditions, blotted on separate PVDF membranes and processed for
detection with the respective antibodies. Densitometric quantification normalized to b-actin levels (right panel). Images are representative of three
independent experiments (* p , 0.05).
www.nature.com/scientificreports
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centrilobular plus periportal; 3 5 bridging; 4 5 cirrhosis). The
mRNA expression of AR in F4 NASH patients was found to be at
a level seven times higher respect to that of liver obtained from
patients not exhibiting NASH. Consistently, the number of HSC
immunopositive for AR in NASH patient liver histological sections
was abundant and only detectable in NASH stages F3 and F4. It is
known that AR expression is minimal in hepatocytes and other cell
types under normal conditions10. In agreement with this 1) AR
mRNA was detectable but at very low levels in human liver without
fibrosis while in NASH F4 livers AR gene expression was much
higher; 2) at the protein levels, inNASHF1 and F2,HSC cells positive
for AR where very rare or absent, as determined by immunohisto-
chemistry. As livers with grade 3 and 4 scores are very fibrotic, the
expression profiles make a strong case that AR is up-regulated in
response to damage to the organ and may be important for wound
healing. However, an over-expression may contribute to develop-
ment of fibrosis and onset of cirrhosis.
Fibrosis and progression to cirrhosis have been identified as pos-
itive factors in the development of cancer, specifically HCC.
Currently, why this relation exists is not known. However, proteins
promoting HSC activation and proliferationmay act as a contributor
to the process. HSCs were recently shown to express WNT and
Hedgehog proteins, both of which have been linked to signaling
pathways involved in carcinogenesis38,39. Furthermore, human AR
is believed to be a target of WNT as it possesses a binding site for the
protein in its promoter40. Thus, mitogens expressed in hHSC such as
AR may aid in cancer progression. In support of this, AR knock-out
animals or knock-downs cell lines have shown a lesser incidence of
HCC characteristics10,11. A future approach would therefore be to
determine whether manipulation of AR would be useful as an
HCC preventative agent in the treatment of patients with cirrhosis.
In conclusion, AR is implicated in liver regeneration, NAFLD and
its fibrogenic form NASH are HCC risk factors, amd hepatic fibro-
genesis involves activation of HSC. We show here that AR activates
HSC function in mouse and human NASH. With relatively few
investigations relating to AR in liver function, the reported results
may be of value in therapeutic applications. We present for the first
time that AR is expressed in hHSC. Our results have also shown that
AR may activate and induce proliferation in hHSC and enhance live
cell populations in primary culture. In keeping with what is known
about stellate cells in liver, their increased proliferation is thought
to be aided by AR during liver wound healing, likely producing a
Figure 6 | AR mRNA is expressed in patients scored for fibrosis according to both Brunt and NAFLD Activity Score (NAS) of fibrosis severity. (A)
Either healthy liver segments of patients undergoing resection of metastases or liver biopsy specimens of patients scored for NASH with fibrosis
(grade 4 according to both Brunt and NAS Score of fibrosis severity) were used to assess AR mRNA expression. Control sections express faint AR levels
while in NASH patients AR levels are considerably elevated. (B) A comparison of samples shows that relative AR expression is six times higher in NASH
livers than in control samples (*p , 0.001).
www.nature.com/scientificreports
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protective layer of extra-cellularmatrix (ECM) that supports repopu-
lating hepatocytes. The data compiled here supports the hypothesis,
as collagen and ASMA production is concurrent with AR-induced
proliferation of hHSC. The observation is complemented in both a
mousemodel of NASH and patient biopsies with NASH. The human
data lends added importance to this study as we suggest that AR
expression may be a component of the liver’s survival response to
NAFLD. However, overproduction of AR may lead to increased
Figure 7 | AR and ASMA expression in liver sections in fibrotic patients with increasing NASH severity (F1 to F4), according to both Brunt and NAS
Scores; (n 5 10). (A) Representative pictures of Masson trichrome staining for collagen (green/blue) in samples with fibrosis F1 to F4. Bar: 100 mm.
Magnification 4003. (B) Representative pictures of AR and ASMA immunostainings. Bar: 100 mm. Arrows indicate positive cells. Magnification 4003;
highlighted insets were obtained with a magnification 10003. (C) The quantification values of AR and ASMA immunopositive cells refer to the average
number of positive cells for High Power Fields (HFP, 4003). Three independent observers examined the specimens. The means of triplicate counts were
used for statistical analyses.
Figure 8 | Scheme illustrating the signaling events induced by amphiregulin and influencing hepatic stellate cell dynamics and fate. Continuous lines
ending with arrows render positive interactions, while continuous line ending with sphere renders negative interaction. TACE 5 tumour necrosis
factor (TNF) a converting enzyme; AR 5 amphiregulin.
www.nature.com/scientificreports
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levels of fibrosis and lead to cirrhosis and potentially HCC. Thus,
regulation of AR may be used to control the severity of the disease,
using a regime that will promote liver recovery but control over-
stimulation and the potential formation of fibrosis.
Methods
Animals.Adult C57/BL6 animals (Charles River Laboratories, UK) 8 to 10 weeks old,
were used. All animal studies were approved by the University Hospitals of Leuven,
Belgium, and all the procedures described have been carried out in accordance with
EU Directive 2010/63/EU for animal experiments. The methionine-choline deficient
(MCD) model is an established dietary model of murine NASH23. After 4 weeks of
MCD or a control diet, mice were sacrificed by asphyxiation with CO2 and cervical
dislocation.
HumanBiopsies andHistological Evaluations. Liver specimens were obtained from
patients undergoing clinically indicated hepatic biopsies, with the approval of the
University of Palermo (Department of Pathology), patient consent and in accordance
with the Code of Ethics of the World Medical Association (Declaration of Helsinki)
for experiments involving humans. Liver biopsy specimens were scored for the
presence of NAFLD according to the Brunt and NAFLD Activity Score (NAS) of
fibrosis severity26,27, by a blinded expert liver pathologist. Liver tissue obtained from
biopsy specimens were flash frozen in liquid nitrogen and stored at minus 80uC or,
alternatively, formalin-fixed paraffin embedded until further use. 10 cases were
selected for each stage of fibrosis score/severity (F1 to F4). From the paraffin blocks,
sections of human liver biopsies with a thickness of 4–5 mm were obtained using a
cutting microtome. After the sections were stained by Masson trichrome staining for
histological evaluation as previously described43.
Immunohistochemistry. Immunostainings were performed by iVIEW DAB
Detection Kit for Ventana BenchMark XT automated slide stainer on human
biopsies43. Primary antibodies for AR (H-155, Santa Cruz Biotechnology) and ASMA
(ACTA-2, SIGMA) were diluted 15100. Positive and negative controls were run
concurrently. For assessment of AR and ASMA cell immunopositivity, the value
expressed refers to the average number of positive cells for High Power Fields (HPF,
4003). Three independent observers examined the specimens. All the observations
were made at a magnification 4003 and the means of triplicate counts were used for
statistical analyses.
Isolation and Culture of Human Primary Hepatic Stellate Cells. hHSC were
obtained, with appropriate local Ethical approval and patient consent, from healthy
liver segments of patients undergoing metastases resection. hHSCs were isolated by
collagenase (type IV) perfusion, followed by pronase treatment, as previously
described21,41. Cell identity was confirmed by autofluorescence, and expression of a-
smooth muscle actin (ASMA), an accepted HSC marker. Experiments were
performed with primary hHSCs in culture as previously described42.
Isolation and Culture of Mouse Primary Hepatic Stellate Cells and Hepatocytes.
Mouse HSCs (mHSCs) were isolated from the livers of wild type andMCDmale mice
by in situ perfusion using collagenase and pronase41,44. The viability and purity ofHSC
preparations were consistently found to be.95% as accessed via trypan blue (Gibco-
BRL, Grand Island, NY, USA) exclusion and autofluorescence, respectively.
Hepatocytes were isolated from wild-type and MCD male mice, purified by Percoll
gradient centrifugation and cultured as previously described41,44.
Immunocytochemistry. hHSC were harvested at days 0, 2, 4, and 10. Subsequently,
the cells were fixed in 50% ethanol/acetic acid and cooled for 10 min at220uC. Fixing
buffer was then removed and the cells washed with PBS and processed for antigen
unmasking using 10 mM sodium citrate and 0.2% Triton X. After blocking with 10%
goat serum (Vector Labs, s-1000) at room temperature for 20 min, the protein of
interest was labeled by incubating the cells overnight at 4uCwith amousemonoclonal
primary antibody (ASMA, sc-32251, AR, sc-74501, Santa Cruz Biotechnology) at a
15400 dilution. The primary antibody binding was later detected using the
appropriate anti-mouse secondary antibody (1510,000 dilution) conjugated with
FITC. DAPI was used in the mounting medium to stain the nuclei and samples
examined by confocal microscopy.
Drugs. EGFR inhibitor PD 153035, pertussis toxin (PT), wortmannin (WT),
PD98059 (PD), SB202190 (SB), and Ro-32-0432 (RO) were obtained from Sigma and
were used on hHSC at concentration previously described20.
Cell Proliferation Assay. Basal and induced hHSC proliferation was determined
using a colorimetric assay45. Optical densities were read from 96-well plates with an
Emax precision microplate reader.
Apoptosis Assay. Equal numbers of hHSC were plated on 6 mm petri dishes with or
without AR. At harvest, apoptotic activity was assessed with the Vybrant (annexin V)
apoptosis assay kit 2 (Molecular Probes, InVitrogen). Flow cytometric analysis was
performed using a Becton-Dickinson flow cytometer.
RT-PCR. RNA was isolated from activated hHSCs using Trizol reagent (Invitrogen)
and DNA generated with Superscript III one-step RT-PCR with platinum Taq kit
(Invitrogen, cat.10928034). Relative quantification of themRNAswas performed on a
Rotorgene RG-3000 instrument (Corbett Research). Collagen 1-a2, TGF-b1, ASMA,
AR andGAPDHprimers were custommade (InVitrogen) while classic II 18S internal
standard kit was from Ambion (Applied Biosystems, UK). Primers sequences,
product sizes and Tm were as follows: Collagen 1a2: sense 59-ATA TTG CAC CTT
TGGACATC39, antisense 59-TGCTCTGATCAATCCTTCTT-39 (236 bp, 55uC);
TGF-b1: sense 59-AAC CCA CAA CGA AAT CTA TG and antisense 59-GTG CTG
CTC CAC TTT TAA CT-39 (157 bp, 55uC).
AR: sense 59-GAC ACC TAC TCCGGGAAAGCG TG-39 and antisense 59-AGC
CAG GTA TTT GTG GTT CG-39 (196 bp, 55uC); TACE: sense 59-GAA GTG CCA
GGA GGC GAT TA-39 and antisense 59-CGG GCA CTC ACT GCT ATT ACC-39
(73 bp, 55uC); GAPDH: sense 59-ACA GTC CAT GCC ATC ACT GCC-39 and
antisense 59-GCC TGC TTC ACC ACC TTC TTG-39 (266 bp, 55uC). To monitor
specificity, final PCR products were analyzed both by melting curves and agarose gel
(1%) electrophoresis. The amount of transcript was calculated and expressed as the
difference relative to the control gene GAPDH (22DDCt, where DCt represents the
difference in threshold cycles between the target and control genes).
Western Blotting. Total caspase-3 was evaluated by western blot analysis, as
previously described46. Briefly, samples were homogenized with RIPA buffer (NaCl,
Tris-HCL, 1% sodium deoxycholate, 0.1% SDS, and 1% NP-40, Sigma) plus protease
cocktail (Roche). Samples ($20 mg protein) were then loaded onto a 10% bis-tris
polyacrylamide gel (Invitrogen, NP301). Western blots were performed using as
primary antibodies caspase-8 (Cell Signaling #9746), b-actin (Santa Cruz
Biotechnology, Santa Cruz, Ca, SC-1616), ADAM17/TACE (Abcam, ab77820) and
amphiregulin (Thermo Scientific, PA5-27298), pEGFR (Y1068) (Abcam, ab5644),
pAKT (Ser473) (Cell Signaling #9271), pERK1/2 (Thr202/Tyr204) (Cell Signaling
#9101) and p-p38 (Thr180/Tyr182) (Cell Signaling #9211) at a dilution of 0.5 mg/ml.
Horseradish peroxidase-conjugated secondary antibodies (SantaCruz Biotechnology,
SC-2031) were used to detect primary antibodies at a 1510,000 dilution ratio. Signals
were detected by an ECL kit (Amersham Pharmacia Biosciences, Piscataway, NJ).
Equal loading (20 mg) was verified by comparing expression levels of b-actin.
TNF-a converting enzyme (TACE) activity. TACE activity was assessed in cultured
hHSC using the commercial fluorimetric SensoLyteH 520 TACE (a-Secretase)
Activity Assay Kit (Anaspec, CA, USA), according to manufacturer’s instructions.
Statistical Analysis. All data are expressed as mean (6SEM) of at least 3 separate
experiments. Statistical analyses were performed using the Mann-Whitney test. A p
value was considered statistically significant if p , 0.05.
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